NVIDIA on January 12, 2026 announced a major expansion of NVIDIA BioNeMo, an open development platform that enables lab-in-the-loop workflows to develop breakthroughs in AI-driven biology and drug discovery. The life sciences industry generates vast amounts of scientific data. BioNeMo provides the development platform to generate and process data, train, optimize and deploy models ?

enabling the industry to turn data into a competitive engine for discovery and maximize the probability of success while minimizing R&D costs, which are currently estimated at $300 billion a year. BioNeMo has now expanded to include: New NVIDIA Clara open models, the RNAPro model for RNA structure prediction and the ReaSyn v2 model for ensuring AI-designed drugs are practical to synthesize. BioNeMo Recipes to easily accelerate and efficiently scale biological foundation model training, customization and deployment.

BioNeMo data processing libraries such as nvMolKit, a GPU-accelerated cheminformatics tool for molecular design.